Lv4
596 积分 2024-09-01 加入
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
25天前
已完结
Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study
1个月前
已完结
Oncological Outcomes in Bacillus Calmette-Guérin–naïve High-risk Non–muscle-invasive Bladder Cancer Patients: A Systematic Review on Current Treatment Strategies and Future Perspectives
1个月前
已完结
The association between statin use, genetic variation, and prostate cancer risk
1个月前
已完结
Comparison of the prognoses after two different surgical procedures plus radiotherapy in the treatment of patients with prostate cancer: survival analysis based on propensity score matching
1个月前
已完结
Cardiovascular Risk Assessment in Prostate Cancer: The Role of Coronary Artery Calcium Scoring
1个月前
已完结
The correlation between discrepancies in clinical and pathological T stages and overall survival in upper urinary tract urothelial carcinoma: Analysis of the hospital‐based cancer registry data in Japan
1个月前
已完结
PARP inhibitors for prostate cancer: for whom and when?
1个月前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide for metastatic castration-resistant prostate cancer: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
1个月前
已完结
First-line talazoparib plus enzalutamide versus placebo plus enzalutamide in men with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: patient-reported outcomes from the randomised, double-blind, placebo-controlled, phase 3 TALAPRO-2 trial
1个月前
已完结
皖公网安备34019202002308
